Assessment of the reporting quality of randomized controlled trials related to the pharmacotherapy of COVID-19 based on the CONSORT 2010 checklist: a systematic review-Reference-Cited by-同舟云学术

Assessment of the reporting quality of randomized controlled trials related to the pharmacotherapy of COVID-19 based on the CONSORT 2010 checklist: a systematic review

Published:2022-04 Issue:4 Volume:28 Page:620-624
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Jung Youn-Joo,Oh Yunkyoung,Purja Sujata,Jeong Hyokeun,Kim EunYoung

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference11 articles.

1. Increasing value and reducing waste in research design, conduct, and analysis;Ioannidis;Lancet,2014

2. Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin;Wang;J Clin Epidemiol,2021

3. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials;Schulz;Ann Intern Med,2010

4. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement;Ziogas;Ann Epidemiol,2009

5. A review of adherence and predictors of adherence to the CONSORT statement in the reporting of tuberculosis vaccine trials;Ngah;Vaccines,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring maternal improvement through multi-stakeholder engagement: Documenting developments in the dynamic programmatic context of the global COVID-19 pandemic through outcome harvesting;Journal of Global Health;2023-06-09

2. Reporting quality was suboptimal in a systematic review of randomized controlled trials with adaptive designs;Journal of Clinical Epidemiology;2023-02

3. Transparency and reporting characteristics of COVID-19 randomized controlled trials;BMC Medicine;2022-09-26